Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes

Autor: Kazunobu Sugawara, Tomonori Tateishi, Tsukasa Uno, Masato Saito, Takenori Takahata, Norio Yasui-Furukori, Akihiro Munakata
Rok vydání: 2005
Předmět:
Zdroj: British Journal of Clinical Pharmacology. 59:302-309
ISSN: 1365-2125
0306-5251
DOI: 10.1111/j.1365-2125.2004.02329.x
Popis: Aims Lansoprazole is a substrate of CYP2C19 and CYP3A. The aim of this study was to compare the inhibitory effects of clarithromycin, an inhibitor of CYP3A on the metabolism of lansoprazole between CYP2C19 genotypes. Methods A two-way randomized double-blind, placebo-controlled crossover study was performed. Eighteen volunteers, of whom six were homozygous extensive metabolizers (EMs), six were heterozygous EMs and six were poor metabolizers (PMs) for CYP2C19, received two 6-day courses of either clarithromycin 800 mg or placebo daily in a randomized fashion with a single oral dose of lansoprazole 60 mg on day 6 in all cases. Plasma concentrations of lansoprazole and its metabolites, 5-hydroxylansoprazole and lansoprazole sulphone were monitored up to 24 h after dosing. Results During placebo administration, the mean AUC(0, ∞) of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml−1 h, 8299 (4784, 11814) ng ml−1 h and 25293 (17643, 32943) ng ml−1 h (P
Databáze: OpenAIRE
Externí odkaz: